Results of a Phase 1/2a gene therapy clinical trial in children with Duchenne muscular dystrophy (DMD) revealed a significant decrease in levels of serum creatine kinase, an enzyme biomarker associated with muscle damage caused by DMD.
Results of a Phase 1/2a gene therapy clinical trial assessing AAVrh74.MHCK7.microdystrophin in children with Duchenne muscular dystrophy (DMD) revealed a significant decrease in levels of serum creatine kinase (CK), an enzyme biomarker associated with muscle damage caused by DMD, according to an announcement from Sarepta Therapeutics.
Sarepta Therapeutics, a commercial stage biopharmaceutical company, presented preliminary data on the first 3 patients enrolled in their clinical trial at the company’s R&D Day. Jerry Mendell, MD, of Nationwide Children’s Hospital, announced the main findings, including:
“I have been waiting my entire 49-year career to find a therapy that dramatically reduces CK levels and creates significant levels of dystrophin. Although the data are early and preliminary, these results, if they persist and are confirmed in additional patients, will represent an unprecedented advancement in the treatment of DMD,” Mendell stated. “I look forward to treating more patients in the clinical study to generate the data necessary to bring this therapy to patients with DMD, with the goal of dramatically changing the course of the disease.”
The trial also did not result in any serious adverse events. Overall, 2 patients had elevated gamma-glutamyl transferase, which resolved within a week using increased steroids. Patients also had transient nausea during the first week of therapy with the increased steroid dosing.
Mendell and Louise Rodino-Klapac, PhD, empirically optimized the AAVrh74.MHCK7 specifically for DMD, according to the study. They described that the AAVrh74 vector can be systemically and robustly delivered to skeletal, diaphragm, and cardiac muscle without excessively crossing the blood brain barrier. Additionally, the MHCK7 promoter has been chosen due to its ability to robustly express in the heart, which is important for patients with DMD because they typically die from pulmonary or cardiac complications.
“While these are early days and work remains to fully understand the full potential of gene therapies, these first signals are encouraging. We remain hopeful that this will lead to a viable treatment for Duchenne,” concluded Pat Furlong, Parent Project Muscular Dystrophy’s founding president and chief executive officer.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More